News | November 12, 2025
JB Pharma Q2 PAT up 19 % at Rs. 208 Cr
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
Net profit for the half-year rose to Rs. 410 crore from Rs. 351 crore
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
Tinostamustine is an investigational drug with a potential first-in-class mechanism combining bifunctional alkylating activity and pan histone deacetylase (HDAC) inhibition
New funding to advance non-surgical brain interface technology and expand clinical and engineering capabilities globally
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
The partnership aligns with the launch of Oracle Health’s next-generation electronic health record
Enabling a new era in minimally invasive obesity treatment across Europe
This approval is based on positive results from two Phase 3, global, double-blind, placebo-controlled trials
The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Venus Remedies now has 29 active product approvals in Vietnam alone
Subscribe To Our Newsletter & Stay Updated
